ELI LILLY AND COMPANY Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31)
ELI LILLY AND COMPANY (LLY) had Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) of $13.03 billion as of 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards
us-gaap:DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateBenefitObligation · last filed 2018-02-20
- 2017-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) $13.03B.
- 2016-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) $10.60B.
- 2015-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) $10.05B.
- 2014-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) $10.54B.
| Period end | Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) | Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Benefit Obligation (Deprecated 2018-01-31) as first filed |
|---|---|---|
| 2017-12-31 | $13.03B 10-K · filed 2018-02-20 | |
| 2016-12-31 | $10.60B 10-K · filed 2018-02-20 | |
| 2015-12-31 | $10.05B 10-K · filed 2017-02-21 | |
| 2014-12-31 | $10.54B 10-K · filed 2016-02-19 | |
| 2013-12-31 | $1.77B 10-K · filed 2015-02-19 | |
| 2012-12-31 | $9.15B 10-K · filed 2014-02-19 | $9.15B 10-K · filed 2013-02-21 |
| 2011-12-31 | $8.12B 10-K · filed 2013-02-21 | $7.03B 10-K · filed 2012-02-24 |
| 2010-12-31 | $1.10B 10-K · filed 2012-02-24 | |
| 2009-12-31 | $1.01B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |